-
The probiotic movement is rapidly growing and, although to date no probiotics have been approved by the FDA, they are actively marketed to the public as either foods or dietary supplements. It behooves the primary care physician to be familiar with the science, indications, and appropriate usage of probiotic therapies.
-
Johnston BC, et al. Comparison of weight loss among named diet programs in overweight and obese adults: A meta-analysis.
-
An objective, laboratory based diagnostic tool for depression would be extremely helpful to primary care physicians. This study using nine biomarkers holds promise that a blood test may be able to identify depressed patients among non-depressed primary care patients
-
The FDA has approved two drugs for the treatment of idiopathic pulmonary fibrosis (IPF). Pirfenidone is an antifibrotic agent and nintedanib is a tyrosine kinase inhibitor. Both products were approved on a fast-track priority review, with orphan status and breakthrough designation. Pirfenidone is marketed by InterMune as Esbriet and nintedanib as Ofev by Boehringer Ingelheim.
-
This 150-day, randomized, double-blind, placebo controlled trial (RCT) with 465 healthy adult volunteers (mean age 37 years old) was designed to examine the effects of probiotics on the incidence of upper respiratory tract infections (URTI).
-
Patients with unprovoked venous thromboembolism (VTE) are at high risk of recurrence after discontinuation of vitamin K antagonist (such as warfarin) therapy, with an approximately 10% risk of recurrence within the first year and 5% risk per year thereafter.
-
Ventilator-associated pneumonia (VAP) is a serious complication for intubated patients. It causes significant morbidity and mortality, increases healthcare costs and is the main reason for antibiotic use in the intensive care unit (ICU).
-
-
Asymptomatic carriage of C. difficile in adult hospitalized patients varies regionally, but estimates suggest that 4% to 23% of patients being admitted to hospital in the U.S. may be colonized with toxogenic strains of C. difficile (TCD).
-
147 patients on stable antiretroviral therapy (ART) were randomized to receiving rosuvustatin 10 mg daily or placebo. After 24 weeks rosovustatin both reduced cystatin C and slowed kidney function decline as assessed by a serum creatinine-based equation.
